Earlier Use of Long-Acting Injectable Paliperidone Palmitate Versus Oral Antipsychotics in Patients With Schizophrenia: An Integrated Patient-Level Post Hoc Analysis

Conclusions: This post hoc analysis suggests that PP provides significant benefit in reducing TF or relapse compared with OAPs regardless of duration of illness and highlights the potential benefit of implementing PP earlier in the course of schizophrenia.Trial Registration: ClinicalTrials.gov identifiers NCT01157351 (PRIDE), NCT01081769 (PROSIPAL), and NCT02431702 (DREaM).PMID:37756123 | DOI:10.4088/JCP.23m14788

Source: Journal of Clinical Psychiatry - September 27, 2023 Category: Psychiatry Authors: Oliver J Lopena Larry D Alphs Martha Sajatovic Ibrahim Turkoz Liping Sun Karen L Johnston Jennifer K Sliwa Dean M Najarian H Lynn Starr Source Type: research